Tonix Pharmaceuticals Announces Oral Presentation and Three Poster Presentations at the 2024 Military Health System Research Symposium (MHSRS)
Rhea-AI Summary
Tonix Pharmaceuticals (Nasdaq: TNXP) announced its participation in the 2024 Military Health System Research Symposium (MHSRS) with one oral presentation and three poster presentations. The oral presentation will highlight TNX-102 SL's efficacy in treating fibromyalgia, demonstrating significant improvement in nociplastic pain and six key secondary endpoints. Poster presentations will cover:
1. TNX-102 SL's potential for acute stress disorder treatment
2. An automated high-throughput assay for wound healing therapeutics
3. The AURORA Platform Trial Network for testing interventions to reduce acute stress reaction symptoms
Tonix recently secured a $34 million contract from the U.S. Department of Defense to develop TNX-4200, a broad-spectrum antiviral agent. The company is preparing to submit a New Drug Application for TNX-102 SL for fibromyalgia management in the second half of 2024.
AI-generated analysis. Not financial advice.
Positive
- TNX-102 SL demonstrated statistically significant improvement in fibromyalgia nociplastic pain and six key secondary endpoints in Phase 3 RESILIENT study
- Secured a $34 million contract from U.S. Department of Defense for TNX-4200 development
- Preparing to submit New Drug Application for TNX-102 SL for fibromyalgia management in H2 2024
- FDA granted Fast Track designation to TNX-102 SL for fibromyalgia management
Negative
- None.
News Market Reaction – TNXP
On the day this news was published, TNXP declined 5.26%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Oral presentation highlights TNX-102 SL (sublingual cyclobenzaprine HCl) treatment in Phase 3 RESILIENT study demonstrating statistically significant improvement in fibromyalgia nociplastic pain and in all six key secondary endpoints, including sleep quality
Posters highlighting other TNX-102 SL programs in clinical development, including acute stress disorder
Poster demonstrating automated high-throughput assay enabling screening for therapeutics to accelerate wound healing
CHATHAM, N.J., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that representatives of the Company will deliver an oral presentation and present three posters at the 2024 Military Health System Research Symposium (MHSRS), being held August 26-29, 2024, in Kissimmee, Fla. Details on the presentations can be found below.
Copies of the Company’s oral presentation and posters will be available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com following the conference. Additional meeting information can be found on the MHSRS website here.
Oral Presentation
| Presenter: | Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals |
| Session: | Assuaging Agony: Novel Pain Therapeutics |
| Title: | Efficacy and Safety of Bedtime TNX-102 SL (Sublingual Cyclobenzaprine HCl) for the Management of Fibromyalgia: Results from the Confirmatory Phase 3 Randomized, Double-Blind, Placebo-Controlled RESILIENT Trial |
| Date/Time: | Tuesday, August 27, 2024, 1:00 p.m. – 3:00 p.m. ET |
Poster Presentations
| Presenter: | Megan Parmenter, Ph.D., Massachusetts General Hospital |
| Title: | Two Clinical Trials of Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) in Military-Related Posttraumatic Stress Disorder (PTSD) Provide Rationale to Study TNX-102 SL in the Aftermath of Trauma to Reduce Acute Stress Disorder (ASD) and Prevent PTSD |
| Date/Time: | Tuesday, August 27, 2024, 3:00 p.m. – 5:00 p.m. ET |
| Presenter: | Sina Bavari, Ph.D., EVP, Infectious Disease Research and Development, Tonix Pharmaceuticals |
| Title: | Integrating Automated High-Throughput Scratch Assay and Cell Painting for Comprehensive Analysis of Cell Migration and Wound Healing |
| Date/Time: | Wednesday, August 28, 2024, 1:00 p.m. - 3:00 p.m. ET |
| Presenter: | Samuel McLean, M.D., Professor of Psychiatry and Emergency Medicine at the UNC School of Medicine |
| Title: | Development of the AURORA Platform Trial Network to Test Interventions to Reduce Acute Stress Reaction Symptoms, and Illustration of Use Testing Sublingual Cyclobenzaprine TNX-102 SL |
| Date/Time: | Tuesday, August 27, 2024, 3:30 p.m. – 5:30 p.m. ET. |
Tonix Pharmaceuticals Holding Corp.*
Tonix is a fully-integrated biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix recently announced the U.S. Department of Defense (DoD), Defense Threat Reduction Agency (DTRA) awarded it a contract for up to
*Tonix’s product development candidates are investigational new drugs or biologics and have not been approved for any indication.
Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners.
This press release and further information about Tonix can be found at www.tonixpharma.com.
Forward Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2024, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.
Investor Contact
Jessica Morris
Tonix Pharmaceuticals
investor.relations@tonixpharma.com
(862) 904-8182
Peter Vozzo
ICR Westwicke
peter.vozzo@westwicke.com
(443) 213-0505
Media Contact
Ray Jordan
Putnam Insights
ray@putnaminsights.com
(949) 245-5432
